Emd Serono Patent-Cliff Exposure & CMS Drug Spending Portfolio

Emd Serono (US): 10 reconciled FDA prescription therapies (6.8% 2025 to 2030 cliff risk), $619.0M 2024 CMS Part D & Medicaid spend, and 90 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies10
2025 to 2030 Patent-Cliff Revenue Exposure6.8%
Primary Portfolio LOE Date2030-01-01
2024 CMS Total Public Spend$619.0M
2024 Medicare Part D Spend$504.1M
2024 Medicaid Spend$114.9M
California HCAI SB 17 Filings90 WAC filings (max 23.9% 2-yr change)